inclusion criteria: 1. adults willing and able to provide informed consent before performing study procedures 2. adults ≥18 years of age at time of informed consent 3. participants must have written notification of laboratory confirmed covid-19 infection performed prior to screening, at a local laboratory by rt-pcr or other commercial or public health assay in any specimen; and participants must be randomized within 72 hours of receiving the above notification of laboratory confirmed covid-19 4. have a mild or moderate form of covid-19 defined as spo2 \> 94% at screening 5. participants must have at least 1 of the following risk factors for severe illness 1. aged 65 years or older 2. hypertension 3. diabetes mellitus 4. chronic lung disease including asthma, chronic obstructive pulmonary disease (copd), and interstitial lung disease (eg, idiopathic pulmonary fibrosis) 5. chronic cardiac conditions, including coronary artery disease (cad), heart failure, congenital heart disease, cardiomyopathy 6. severe obesity (body mass index \[bmi\] ≥ 40 kg/m\^2) 7. chronic liver disease, including cirrhosis 6. must agree not to enroll in another study of an investigational agent or take any other drug that has been granted emergency use authorization prior to completion of day 28 7. if women of childbearing potential (wocbp) or men whose sexual partners are wocbp, must be able and willing to use at least 1 highly effective method of contraception during the study and for 90 days after receiving the last dose of study drug

inclusion criteria: 1. adults willing and able to provide informed consent before performing study procedures 2. adults ≥18 years of age at time of informed consent 3. participants must have written notification of laboratory confirmed covid-19 infection performed prior to screening, at a local laboratory by rt-pcr or other commercial or public health assay in any specimen; and participants must be randomized within 72 hours of receiving the above notification of laboratory confirmed covid-19 4. have a mild or moderate form of covid-19 defined as spo2 \> 94% at screening 5. participants must have at least 1 of the following risk factors for severe illness 1. aged 65 years or older 2. hypertension 3. diabetes mellitus 4. chronic lung disease including asthma, chronic obstructive pulmonary disease (copd), and interstitial lung disease (eg, idiopathic pulmonary fibrosis) 5. chronic cardiac conditions, including coronary artery disease (cad), heart failure, congenital heart disease, cardiomyopathy 6. severe obesity (body mass index \[bmi\] ≥ 40 kg/m\^2) 7. chronic liver disease, including cirrhosis 6. must agree not to enroll in another study of an investigational agent or take any other drug that has been granted emergency use authorization prior to completion of day 28 7. if women of childbearing potential (wocbp) or men whose sexual partners are wocbp, must be able and willing to use at least 1 highly effective method of contraception during the study and for 90 days after receiving the last dose of study drug

inclusion criteria: adults willing and able to provide informed consent before performing study procedures adults ≥18 years of age at time of informed consent participants must have written notification of laboratory confirmed covid-19 infection performed prior to screening, at a local laboratory by rt-pcr or other commercial or public health assay in any specimen; and participants must be randomized within 72 hours of receiving the above notification of laboratory confirmed covid-19 have a mild or moderate form of covid-19 defined as spo2 > 94% at screening participants must have at least 1 of the following risk factors for severe illness aged 65 years or older hypertension diabetes mellitus chronic lung disease including asthma, chronic obstructive pulmonary disease (copd), and interstitial lung disease (eg, idiopathic pulmonary fibrosis) chronic cardiac conditions, including coronary artery disease (cad), heart failure, congenital heart disease, cardiomyopathy severe obesity (body mass index [bmi] ≥ 40 kg/m^2) chronic liver disease, including cirrhosis must agree not to enroll in another study of an investigational agent or take any other drug that has been granted emergency use authorization prior to completion of day 28 if women of childbearing potential (wocbp) or men whose sexual partners are wocbp, must be able and willing to use at least 1 highly effective method of contraception during the study and for 90 days after receiving the last dose of study drug

inclusion criteria: adults willing and able to provide informed consent before performing study procedures adults ≥18 years of age at time of informed consent participants must have written notification of laboratory confirmed covid-19 infection performed prior to screening, at a local laboratory by rt-pcr or other commercial or public health assay in any specimen; and participants must be randomized within 72 hours of receiving the above notification of laboratory confirmed covid-19 have a mild or moderate form of covid-19 defined as spo2 > 94% at screening participants must have at least 1 of the following risk factors for severe illness aged 65 years or older hypertension diabetes mellitus chronic lung disease including asthma, chronic obstructive pulmonary disease (copd), and interstitial lung disease (eg, idiopathic pulmonary fibrosis) chronic cardiac conditions, including coronary artery disease (cad), heart failure, congenital heart disease, cardiomyopathy severe obesity (body mass index [bmi] ≥ 40 kg/m^2) chronic liver disease, including cirrhosis must agree not to enroll in another study of an investigational agent or take any other drug that has been granted emergency use authorization prior to completion of day 28 if women of childbearing potential (wocbp) or men whose sexual partners are wocbp, must be able and willing to use at least 1 highly effective method of contraception during the study and for 90 days after receiving the last dose of study drug

inclusion criteria: 1. adults willing and able to provide informed consent before performing study procedures 2. adults ≥18 years of age at time of informed consent 3. participants must have written notification of laboratory confirmed covid-19 infection performed prior to screening, at a local laboratory by rt-pcr or other commercial or public health assay in any specimen; and participants must be randomized within 72 hours of receiving the above notification of laboratory confirmed covid-19 4. have a mild or moderate form of covid-19 defined as spo2 > 94% at screening 5. participants must have at least 1 of the following risk factors for severe illness 1. aged 65 years or older 2. hypertension 3. diabetes mellitus 4. chronic lung disease including asthma, chronic obstructive pulmonary disease (copd), and interstitial lung disease (eg, idiopathic pulmonary fibrosis) 5. chronic cardiac conditions, including coronary artery disease (cad), heart failure, congenital heart disease, cardiomyopathy 6. severe obesity (body mass index [bmi] ≥ 40 kg/m^2) 7. chronic liver disease, including cirrhosis 6. must agree not to enroll in another study of an investigational agent or take any other drug that has been granted emergency use authorization prior to completion of day 28 7. if women of childbearing potential (wocbp) or men whose sexual partners are wocbp, must be able and willing to use at least 1 highly effective method of contraception during the study and for 90 days after receiving the last dose of study drug

inclusion criteria: 1. adults willing and able to provide informed consent before performing study procedures 2. adults ≥18 years of age at time of informed consent 3. participants must have written notification of laboratory confirmed covid-19 infection performed prior to screening, at a local laboratory by rt-pcr or other commercial or public health assay in any specimen; and participants must be randomized within 72 hours of receiving the above notification of laboratory confirmed covid-19 4. have a mild or moderate form of covid-19 defined as spo2 > 94% at screening 5. participants must have at least 1 of the following risk factors for severe illness 1. aged 65 years or older 2. hypertension 3. diabetes mellitus 4. chronic lung disease including asthma, chronic obstructive pulmonary disease (copd), and interstitial lung disease (eg, idiopathic pulmonary fibrosis) 5. chronic cardiac conditions, including coronary artery disease (cad), heart failure, congenital heart disease, cardiomyopathy 6. severe obesity (body mass index [bmi] ≥ 40 kg/m^2) 7. chronic liver disease, including cirrhosis 6. must agree not to enroll in another study of an investigational agent or take any other drug that has been granted emergency use authorization prior to completion of day 28 7. if women of childbearing potential (wocbp) or men whose sexual partners are wocbp, must be able and willing to use at least 1 highly effective method of contraception during the study and for 90 days after receiving the last dose of study drug